Skip to Content
Merck
  • Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?

Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?

Journal of nephrology (2014-04-24)
Luca Vergano, Elisa Loiacono, Roberto Albera, Rosanna Coppo, Roberta Camilla, Licia Peruzzi, Alessandro Amore, Maria Elena Donadio, Federica Chiale, Alberto Boido, Filippo Mariano, Gianna Mazzucco, Sara Ravera, Giovanni Cancarini, Riccardo Magistroni, Giulietta Beltrame, Cristiana Rollino, Piero Stratta, Marco Quaglia, Roberto Bergia, Raffaella Cravero, Stefano Cusinato, Luisa Benozzi, Silvana Savoldi, Carola Licata
ABSTRACT

The benefits of tonsillectomy in IgA nephropathy (IgAN) are still debated. Tonsillectomy may remove pathogen sources and reduce the mucosal associated lymphoid tissue (MALT), limiting degalactosylated IgA1 (deGal-IgA1) production, which is considered to be the initiating pathogenetic event leading to IgA glomerular deposition. In the European network VALIGA, 62/1147 IgAN patients underwent tonsillectomy (TxIgAN). In a cross-sectional study 15 of these patients were tested and compared to 45 non-tonsillectomized IgAN (no-TxIgAN) and healthy controls (HC) regarding levels of deGal-IgA1, and markers of innate immunity and oxidative stress, including toll-like receptors (TLR)2, 3, 4 and 9 mRNAs, proteasome (PS) and immunoproteasome (iPS) mRNAs in peripheral blood mononuclear cells (PBMC), and advanced oxidation protein products (AOPP). Levels of deGal-IgA1 were lower in TxIgAN than in no-TxIgAN (p = 0.015), but higher than in HC (p = 0.003). TLR mRNAs were more expressed in TxIgAN than in HC (TLR4, p = 0.021; TLR9, p = 0.027), and higher in TxIgAN than in no-TxIgAN (p ≤ 0.001 for TLR2, 4, 9). A switch from PS to iPS was detected in PBMC of TxIgAN in comparison to HC and it was higher than in no-TxIgAN [large multifunctional peptidase (LMP)2/β1, p = 0.039; LPM7/β5, p < 0.0001]. The levels of AOPP were significantly higher in TxIgAN than HC (p < 0.001) and no-TxIgAN (p = 0.033). In conclusion, the activation of innate immunity via TLRs and ubiquitin-proteasome pathways and the pro-oxidative milieu were not affected by tonsillectomy, even though the levels of aberrantly galactosylated IgA1 were lower in patients with IgAN who had tonsillectomy. The residual hyperactivation of innate immunity in tonsillectomized patients may result from extra-tonsillar MALT.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate, suitable for enzyme immunoassay, ≥99.0% (enzymatic)
Sigma-Aldrich
Potassium iodide, tested according to Ph. Eur.
Sigma-Aldrich
Potassium iodide, ≥99.99% trace metals basis
Sigma-Aldrich
Phosphatase substrate, powder
Sigma-Aldrich
Phosphatase substrate, 40 mg capsules
Sigma-Aldrich
Phosphatase substrate, 40 mg tablets
Sigma-Aldrich
Phosphatase substrate, 100 mg capsules
Sigma-Aldrich
Potassium iodide, AnhydroBeads, −10 mesh, 99.998% trace metals basis
Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Potassium iodide, BioUltra, ≥99.5% (AT)
Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate, tablet
Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate, tablet
Sigma-Aldrich
Potassium iodide, suitable for plant cell culture
Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate, tablet
Sigma-Aldrich
Potassium iodide, BioXtra, ≥99.0%
Sigma-Aldrich
Phosphatase substrate, 5 mg tablets
Sigma-Aldrich
Potassium iodide, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99%
Sigma-Aldrich
Phosphatase substrate, Suitable for manufacturing of diagnostic kits and reagents
Sigma-Aldrich
Potassium iodide, puriss., meets analytical specification of Ph. Eur. BP, USP, 99.0-100.5% (calc. to the dried substance)
Supelco
Potassium Iodide, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Potassium iodide, puriss. p.a., reag. ISO, reag. Ph. Eur., ≥99.0%
Sigma-Aldrich
Potassium iodide, puriss., meets analytical specification of Ph. Eur. BP, USP, 99.0-100.5% (calc. to the dried substance)
Sigma-Aldrich
Potassium iodide, ReagentPlus®, 99%
Sigma-Aldrich
Potassium iodide, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Sigma-Aldrich
Potassium iodide, ACS reagent, ≥99.0%